*	OR T1 T2 T4
R1	Has_multiplier Arg1:T4 Arg2:T3	
R2	Has_temporal Arg1:T1 Arg2:T5	
R3	Has_temporal Arg1:T7 Arg2:T8	
R4	Has_value Arg1:T10 Arg2:T11	
R5	Subsumes Arg1:T9 Arg2:T10	
R6	Subsumes Arg1:T7 Arg2:T9	
R7	Has_mood Arg1:T14 Arg2:T15	
R9	Has_value Arg1:T19 Arg2:T20	
*	OR T17 T18
R8	AND Arg1:T16 Arg2:T17	
T1	Drug 18 21	HES
T2	Drug 23 41	dextrane solutions
T3	Multiplier 45 53	> 500 ml
T4	Drug 57 74	Gelatin solutions
T5	Temporal 75 113	within the 24 h prior to randomization
T7	Observation 115 129	Death expected
T8	Temporal 130 150	within the next 48 h
T9	Condition 152 160	moribund
T10	Measurement 184 187	ASA
T11	Value 188 197	= class V
T12	Non-query-able 200 264	Patients whose medical condition does preclude the PLR manoeuvre
T13	Non-representable 266 327	Patients for whom the need of pressure infusions are expected
T14	Condition 345 358	renal support
T15	Mood 329 344	Requirement for
T16	Drug 517 524	heparin
T17	Condition 543 570	chronic coagulation disease
T18	Drug 573 599	anticoagulation medication
T19	Measurement 606 633	partial thromboplastin time
T20	Value 634 642	> 60 sec
T22	Condition 645 659	Acutely burned
T23	Non-representable 670 781	Contraindications according to summary of product characteristics of investigational test and reference product
T24	Non-query-able 783 885	Simultaneous participation in another interventional clinical trial (drugs or medical devices studies)
